BoomRay Pharmaceuticals

General Information

Company Name

Founded Year

2020

Location (Offices)

Suzhou, China +1

Founders / Decision Makers

Number of Employees

Industries

Biopharma, Biotechnology, Health Care

Funding Stage

Series A

Social Media

BoomRay Pharmaceuticals - Company Profile

WuXi Bo Rui Biotechnology, founded in 2020, is pioneering precise diagnostics and treatments for tumors through advanced radionuclide drug development and innovative molecular imaging platforms. Specializing in creating a platform for precise tumor diagnosis and treatment through radioactive molecular imaging and nuclear drug innovation, the company focuses on developing new radionuclide drugs, encompassing small molecules, peptides, and antibodies. Utilizing their expert platform for targeted precursor design, screening, and radionuclide labeling, they enhance research and development efficiency while capitalizing on the advantages of accurate nuclear medicine for both diagnosis and treatment. The company has recently secured a CNY290.00M Series A investment on 02 September 2022, with investment from Puhua Capital, Riverhead Capital Investment Management, Sequoia China, Tririver Capital. WuXi Bo Rui Biotechnology operates in the Biopharma, Biotechnology, and Health Care industries, driving innovation and advancements in the field of precise tumor diagnostics and treatments.

Taxonomy: precision medicine, radionuclide drug development, molecular imaging, tumor diagnostics, nuclear medicine, targeted therapy, oncology, radiopharmaceuticals, cancer treatment, small molecules, peptide therapy, antibody therapy